Developing Countries Vaccine Manufacturers Network

Last updated

The Developing Countries Vaccine Manufacturers Network (DCVMN) is a voluntary non-partisan public health alliance of health organizations and vaccine manufacturers. It has the goal of protecting people globally against known and emerging infectious diseases through the provision of a consistent supply of high quality vaccines at affordable prices for developing countries, to achieve vaccine equity. [1] [2] [3] DCVMN includes manufacturers in Brazil, China, Cuba, India, Indonesia, Mexico, South Africa and other low and middle income countries (LMICs). [4] It was established in 2000 [5] /2001, [6] and is headquartered in Switzerland. [5] As of 2021, the President is Sai D. Prasad, [7] and the CEO is Rajinder Suri. [8]

In 2018, DCVMN members supplied more than half of the 2.36 billion doses of vaccines used globally by UNICEF. [9] In 2019, a survey of 41 DCVMN members assessed their ability to use technology platforms, cell cultures and filling technologies for the manufacture of drug products. DCVMN members reported that they had the capability to supply over 50 distinct vaccines to 170 countries, totalling more than 3.5 billion vaccine doses annually. [10]

At least 15 manufacturer members have achieved WHO prequalification for their vaccines. [9] Members are developing and producing novel vaccines for illnesses including neglected tropical diseases: [11] rotavirus, Japanese encephalitis, pertussis, [12] haemophilus influenzae, hepatitis B, [13] hepatitis E, meningitis A, [3] cholera, poliovirus, human papillomavirus infection, dengue fever, Chikungunya virus and COVID-19. [10] [14]

Developing countries that have the capacity for production of whole inactivated virus (WIV) and protein-based vaccines may be critical in addressing COVID-19 vaccine access gaps and achieving vaccine equity for LMICs. [4] As of 29 December 2020, 18 DCVMN members were involved in preclinical or clinical trials for possible COVID-19 vaccines, three of them in Phase III trials. [10] The DCVMN is a vaccine manufacturers partner of COVAX, a worldwide initiative for equitable access to COVID-19 vaccines. [15] [16]

As of 2016, the timeline from a vaccine's first regulatory submission in its country of origin to its approval for use in Sub-Saharan Africa could take up to seven years. [17] [18] The DCVMN is active in identifying obstacles in the processes of vaccine registration and use. It works to increase coordination of requirements and procedures to improve the prequalification, procurement and supply of vaccines. This can involve governments in different countries, the World Health Organization (WHO), and United Nations agencies such as UNICEF. [17] [19] [20]

The Developing Countries Vaccine Manufacturers Network has received funding from the Bill & Melinda Gates Foundation. [5]

Related Research Articles

<span class="mw-page-title-main">Vaccine</span> Pathogen-derived preparation that provides acquired immunity to an infectious disease

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and recognize further and destroy any of the microorganisms associated with that agent that it may encounter in the future.

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable. Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the pathogen.

Sabin Vaccine Institute (Sabin), located in Washington, D.C., is a nonprofit organization promoting global vaccine development, availability, and use. Through its work, Sabin hopes to reduce human suffering by preventing the spread of vaccine-preventable, communicable disease in humans through herd immunity and mitigating the poverty caused by these diseases.

Anti-vaccinationism in chiropractic is widespread, but there are notable differences within the trade. Chiropractic is a form of alternative medicine founded on the idea that all disease is caused by disruption of the flow of "innate" in the spine, by so-called vertebral subluxations – a pseudoscientific concept. Over time chiropractic has divided into "straights" who adhere to the subluxation theory and "mixers" who adhere more closely to a reality-based view of anatomy. "Straight" chiropractors are very likely to be anti-vaccination, but all chiropractic training tends to reduce acceptance of vaccines.

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

In the pharmaceutical industry, fill and finish is the process of filling vials with vaccine, biological and pharmaceutical Drug Substances (DS) and finishing the process of packaging the medicine for distribution. Many vaccine manufacturers use third parties to fill and finish their vaccines.

<span class="mw-page-title-main">Vaccine Safety Net</span> Network of medical information websites

Vaccine Safety Net (VSN) is a global network of websites aimed at helping people judge the quality of online information on vaccine safety. It was established in 2003 by the World Health Organization (WHO), which had previously set up the independent Global Advisory Committee on Vaccine Safety (GACVS), prompted by concern from public health officials regarding the dissemination of potentially harmful health information via the web. By appraising websites, using credibility and content criteria defined by GACVS, the VSN has been developed to deliver information that is easy to access and up-to-date. As of 2020, the initiative has 89 member sites in 40 countries and 35 languages.

The Global Advisory Committee on Vaccine Safety (GACVS) is a group of experts that provides independent and authoritative guidance to the World Health Organization (WHO) on the topic of safe vaccine use.

Misinformation related to immunization and the use of vaccines circulates in mass media and social media in spite of the fact that there is no serious hesitancy or debate within mainstream medical and scientific circles about the benefits of vaccination. Unsubstantiated safety concerns related to vaccines are often presented on the internet as being scientific information. A high proportion of internet sources on the topic are "inaccurate on the whole" which can lead people searching for information to form "significant misconceptions about vaccines".

<span class="mw-page-title-main">Deployment of COVID-19 vaccines</span> Distribution and administration of COVID-19 vaccinations

As of 16 October 2023, 13.4 billion COVID-19 vaccine doses have been administered worldwide, with 67.9 percent of the global population having received at least one dose. While 4.19 million vaccines were then being administered daily, only 22.3 percent of people in low-income countries had received at least a first vaccine by September 2022, according to official reports from national health agencies, which are collated by Our World in Data.

<span class="mw-page-title-main">ZyCoV-D</span> Vaccine candidate against COVID-19

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

<span class="mw-page-title-main">Vaccine wastage</span>

Vaccine wastage is the number of vaccines that have not been administered during vaccine deployment in an immunization program. The wastage can occur at multiple stages of the deployment process, and can take place in both unopened and opened vials, or in oral admission. It is an expected part of vaccination deployment and is factored into the manufacturing process.

<span class="mw-page-title-main">Diana Martin (scientist)</span> New Zealand microbiologist (1942–2019)

Diana Rae Martin was a New Zealand microbiologist. She was a Fellow of the Royal Society Te Apārangi from 2000, and was made an Officer of the New Zealand Order of Merit for services to microbiology in 2008.

Fractional dose vaccination is a strategy to reduce the dose of a vaccine to achieve a vaccination policy goal that is more difficult to achieve with conventional vaccination approaches, including deploying a vaccine faster in a pandemic, reaching more individuals in the setting of limited healthcare budgets, or minimizing side effects due to the vaccine.

Matrix-M is a vaccine adjuvant, a substances that is added to various vaccines to stimulate the immune response. It was patented in 2020 by Novavax and is composed of nanoparticles from saponins extracted from Quillaja saponaria (soapbark) trees, cholesterol, and phospholipids. It is an immune stimulating complex (ISCOM), which are nanospheres formed when saponin is mixed with two types of fats.

Vaccine equity means ensuring that everyone in the world has equal access to vaccines. The importance of vaccine equity has been emphasized by researchers and public health experts during the COVID-19 pandemic but is relevant to other illnesses and vaccines as well. Historically, world-wide immunization campaigns have led to the eradication of smallpox and significantly reduced polio, measles, tuberculosis, diphtheria, whooping cough, and tetanus.

<span class="mw-page-title-main">Suresh Jadhav (biotechnology executive)</span> Indian biotechnology executive (died 2021)

Suresh Jadhav was an Indian biotechnology executive and a key member of the Indian vaccine manufacturing industry. At the Serum Institute of India (SII) he led the development and introduction of the Meningococcal A conjugate vaccine to Sub-Saharan Africa and the production of the COVID-19 vaccine at SII, including the ones marketed as Covishield.

<span class="mw-page-title-main">Initiative for Medicines, Access, and Knowledge</span> Nonprofit organization

The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global 501(c)(3) organization that advocates in the public interest for affordable access to medicines, and a medicines system that is more inclusive of patients and the public.

Karen Canfell is an Australian epidemiologist and cancer researcher.

References

  1. ↑ "DCVMN". Developing Countries Vaccine Manufacturers Network. Retrieved 26 April 2022.
  2. ↑ Poeloengan, Thamrin; Raw, Isaias; Martinez, Luis Herrera; El-Abbadi, Mohamed (12 November 2001). "Developing Country Vaccine Manufacturers Network (DCVMN), 26–27 April 2001, Bandung, Indonesia". Vaccine. 20 (3): 285–287. doi:10.1016/S0264-410X(01)00333-4. ISSN   0264-410X. PMID   11672886 . Retrieved 26 April 2022.
  3. 1 2 Pagliusi, Sonia; Makhoana, Morena; Datla, Mahima; Leite, Luciana; Hendriks, Jan; Gholami, Alireza; Huang, Weidan; Gao, Yongzhong; Jadhav, Suresh; Harshavardhan, Gutla V. J. A.; Wu, Yonglin; Suhardono, Mahendra; Homma, Akira (28 June 2013). "Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012". Vaccine. 31 (31): 3111–3115. doi:10.1016/j.vaccine.2013.04.082. ISSN   1873-2518. PMID   23684836 . Retrieved 26 April 2022.
  4. 1 2 Hotez, Peter J.; Bottazzi, Maria Elena (27 January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi: 10.1146/annurev-med-042420-113212 . ISSN   0066-4219. PMID   34637324. S2CID   238747462 . Retrieved 26 April 2022.
  5. 1 2 3 "Developing Countries Vaccine Manufactures Network (DCVMN) International". Devex. Retrieved 26 April 2022.
  6. ↑ Hendriks, Jan; Blume, Stuart (7 July 2016). "Why might regional vaccinology networks fail? The case of the Dutch-Nordic Consortium". Globalization and Health. 12 (1): 38. doi: 10.1186/s12992-016-0176-6 . ISSN   1744-8603. PMC   4936226 . PMID   27388678.
  7. ↑ Mascarenhas, Anuradha (17 December 2021). "Great success in vaccine development, but inequity has to be addressed, says expert". The Indian Express. Retrieved 27 April 2022.
  8. ↑ "Challenges and solutions to scaling-up COVID-19 vaccine manufacturing capacity". IFPMA. Retrieved 27 April 2022.
  9. 1 2 Hayman, Benoit; Pagliusi, Sonia (29 April 2020). "Emerging vaccine manufacturers are innovating for the next decade". Vaccine: X. 5: 100066. doi:10.1016/j.jvacx.2020.100066. ISSN   2590-1362. PMC   7242873 . PMID   32462140.
  10. 1 2 3 Hayman, Benoit; Dennehy, Maureen (23 August 2021). "Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization". Vaccine. 39 (36): 5153–5161. doi:10.1016/j.vaccine.2021.07.044. ISSN   1873-2518. PMC   8330991 . PMID   34362602.
  11. ↑ Jadhav, S.; Gautam, M.; Gairola, S. (May 2014). "Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices". Clinical Microbiology and Infection. 20: 37–44. doi: 10.1111/1469-0691.12568 . PMID   24476201 . Retrieved 26 April 2022.
  12. ↑ Pagliusi, Sonia; Leite, Luciana C.C.; Datla, Mahima; Makhoana, Morena; Gao, Yongzhong; Suhardono, Mahendra; Jadhav, Suresh; Harshavardhan, Gutla V.J.A.; Homma, Akira (April 2013). "Developing Countries Vaccine Manufacturers Network: Doing good by making high-quality vaccines affordable for all" (PDF). Vaccine. 31: B176–B183. doi:10.1016/j.vaccine.2012.11.060. PMID   23598479 . Retrieved 27 April 2022.
  13. ↑ Jadhav, Suresh; Datla, Mahima; Kreeftenberg, Hans; Hendriks, Jan (20 March 2008). "The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries". Vaccine. 26 (13): 1611–1615. doi:10.1016/j.vaccine.2008.01.034. ISSN   0264-410X. PMID   18294742 . Retrieved 26 April 2022.
  14. ↑ Pagliusi, Sonia; Jarrett, Stephen; Hayman, Benoit; Kreysa, Ulrike; Prasad, Sai D.; Reers, Martin; Hong Thai, Pham; Wu, Ke; Zhang, Youn Tao; Baek, Yeong Ok; Kumar, Anand; Evtushenko, Anatoly; Jadhav, Suresh; Meng, Weining; Dat, Do Tuan; Huang, Weidan; Desai, Samir (22 July 2020). "Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply". Vaccine. 38 (34): 5418–5423. doi:10.1016/j.vaccine.2020.06.022. ISSN   0264-410X. PMC   7287474 . PMID   32600908.
  15. ↑ "Biotech, Developing and Developed Countries Vaccine Manufacturers COVID-19 Press Briefing (16 December 2021)". International Federation of Pharmaceutical Manufacturers and Associations. Retrieved 26 April 2022.
  16. ↑ "COVAX Manufacturing Task Force to tackle vaccine supply challenges". GAVI. Retrieved 26 April 2022.
  17. 1 2 Dellepiane, Nora; Pagliusi, Sonia (21 May 2019). "Opportunities for improving access to vaccines in emerging countries through efficient and aligned registration procedures: An industry perspective". Vaccine. 37 (23): 2982–2989. doi: 10.1016/j.vaccine.2019.03.025 . ISSN   0264-410X. PMID   31027928. S2CID   135439603.
  18. ↑ Ahonkhai, Vincent; Martins, Samuel F.; Portet, Alexandre; Lumpkin, Murray; Hartman, Dan (16 November 2016). "Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization". PLOS ONE. 11 (11): e0166515. Bibcode:2016PLoSO..1166515A. doi: 10.1371/journal.pone.0166515 . ISSN   1932-6203. PMC   5112794 . PMID   27851831.
  19. ↑ Dellepiane, Nora; Pagliusi, Sonia (7 June 2018). "Challenges for the registration of vaccines in emerging countries: Differences in dossier requirements, application and evaluation processes". Vaccine. 36 (24): 3389–3396. doi:10.1016/j.vaccine.2018.03.049. ISSN   0264-410X. PMC   6278877 . PMID   29724510.
  20. ↑ Hayman, Benoit; Bowles, Alex; Evans, Beth; Eyermann, Elizabeth; Nepomnyashchiy, Lyudmila; Pagliusi, Sonia (22 February 2021). "Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities". Vaccine. 39 (8): 1190–1194. doi:10.1016/j.vaccine.2020.12.085. ISSN   0264-410X. PMC   7909323 . PMID   33487466 . Retrieved 26 April 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.